Bacterial flora in irritable bowel syndrome: Role in pathophysiology, implications for management

Journal of Digestive Diseases

Volumn 8, Issue 1, 2007, Pages 2-7

  Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antibiotic; Enteric flora; Irritable bowel syndrome; Mucosal inflammation; Probiotic

Indexed keywords

EID: 43649100298     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1443-9573.2007.00277.x     Document Type: Article

References (61)

1. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepatol 1998; 10: 59-62.
2. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002; 97: 104-8.
3. McKendrick MW, Read MW. Irritable bowel syndrome - post-salmonella infection. J Infect 1994; 29: 1-3.
4. Neal KR, Hebdon J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome. Br Med J 1997; 314: 779-82.
5. Garcia Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. Br Med J 1999; 318: 565-6.
6. Gwee KA, Graham JC, McKendrick MW et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 150-3.
7. Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in post-infective gut dysfunction. Gut 1999; 44: 400-6.
8. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
9. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-9.
10. Mearin F, Perez-Oliveras M, Perello A et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129: 98-104.
11. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM; Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131: 445-50.
12. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124: 1662-571.
13. Chadwick V, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
14. Collins SM. A case for an immunological basis for irritable bowel syndrome. Gastroenterology 2002; 122: 2078-80. 15 Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-3.
15. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-3.
16. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
17. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-9.
18. O'Mahony L, McCarthy J, Kelly P et al. A Randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
19. Dinan TG, Quigley EM, Ahmed SM et al. Hypothalamic- pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-11.
20. Spiller RC. Role of nerves in enteric infection. Gut 2002; 51: 759-62.
21. Bradley HK, Wyatt GM, Bayliss CE, Hunter JO. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987; 23: 29-32.
22. Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802-5.
23. Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-82.
24. Matto J, Maunuksela L, Kajander K et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43: 213-22.
25. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187-9.
26. Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci 2005; 50: 758-66.
27. Pimentel M, Chow EJ, Lin HC. Eradication of small bowel bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-6.
28. Pimentel M, Chow E, Lin H. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-9.
29. McCallum R, Schultz C, Sostarich S. Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant IBS (IBS-D) patients utilizing the glucose breath test. Gastroenterology 2005; 128: T1118.
30. Nucera G, Gabrielli A, Lupascu A et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 21: 1391-5.
31. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006; 52: 89-95.
32. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002; 47: 2639-43.
33. Cuoco L, Cammarota G, Jorizzo R et al. Small intestinal bacterial overgrowth and symptoms of irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2281-2.
34. Jones MP, Craig R, Olinger E. Small intestinal bacterial overgrowth is associated with irritable bowel syndrome: the cart lands squarely in front of the horse. Am J Gastroenterol 2001; 96: 3204-5.
35. Mishkin D, Mishkin S. Re: Pimentel et al. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2505-6.
36. Riordan SM, McIver CJ, Duncombe VM et al. Small intestinal bacterial overgrowth and the irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2506-8.
37. Hasler WL. Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air? Gastroenterology 2003; 125: 1898-900.
38. Simrén M, Stotzer P-O. Use and abuse of hydrogen breath tests. Gut 2006; 55: 297-393.
39. Parisi G, Leandro G, Bottona E et al. Small intestinal bacterial overgrowth and irritable bowel syndrome. Am J Gastroenterol 2003; 98: 2572.
40. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-d-Xylose and healthy controls. Am J Gastroenterol 2005; 100: 1566-70.
41. Posserud I, Ringström G, Stotzer PO et al. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome (IBS). Neurogastroenterol Motil 2004; 16: 839.
42. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Ell-Iajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326-33.
43. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome : a randomized trial. Ann Intern Med 2006; 145: 557-63. 44 Drossman DA. Treatment for bacterial overgrowth in the irritable bowel syndrome. An Intern Med 2006; 145: 626-8.
44. Drossman DA. Treatment for bacterial overgrowth in the irritable bowel syndrome. An Intern Med 2006; 145: 626-8.
45. Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with lacteol fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996; 91: 1579-85.
46. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32: 302-4.
47. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-8.
48. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001; 152: 735-41.
49. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-7.
50. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-20.
51. Bazzocchi G, Gionchetti P, Almerigi PF, Amadini C, Campieri M. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 2002; 34 (Suppl 2): s48-53.
52. Parker P, McNaught CE, Anderson ADG, Mitchell CJ, MacFie J. Synbiotic in irritable bowel syndrome: a double blind prospective randomised controlled trial. Gut 2003; 52: A11.
53. Kim HJ, Camilleri M, McKenzie S, Lempke MB, Burton DD. A randomized controlled trail of a probiotic, VSL#3 on gut transit and symptoms in diarrhoea-predominant IBS. Aliment Pharmacol Ther 2003; 17: 895-904.
54. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004; 5: 169-74.
55. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005; 147: 197-201.
56. Kim HJ, Vazquez Roque MI, Camilleri M et al. A randomized controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating. Neurogastroenterol Motil 2005; 17: 687-96.
57. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387-94.
58. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925-31.
59. Hamilton-Miller JMT. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb Ecol Health Dis 2001; 13: 212-6.
60. Whorwell PJ, Altinger L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 326-33.
61. Quigley EM. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dig Dis 2005; 6: 122-32.